Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoLIPA
2023-508649-42-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxotemitide and pembrolizumab in melanoma, sponsored by Oslo University Hospital. Primary endpoint: Rate of pathologic complete response (pCR). Planned start Apr 2024; status: authorised.
02
Drugs
ruxotemitidepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-508649-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508649-42-00.